The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Angelini Ventures has already invested €125 million in 22 startups
GV20 received an upfront payment and is eligible for additional milestone payments
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Subscribe To Our Newsletter & Stay Updated